NovoCure Ltd (NVCR): who owns it and who trades it
As of Nov 16, 2026, NVCR insiders reported 20 open-market sales worth $3M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was William F Doyle (Chair), with $933K. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling NovoCure
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NVCR
214 funds and institutions reported NVCR shares worth $1.6B at the end of Q2 2026, about 90% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) 90%Everyone else 10%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 17.37M | 15.00% | $263M | +2% |
| BlackRock, Inc. | 13.41M | 11.58% | $203M | +2% |
| Soleus Capital Management, L.P. | 9.91M | 8.56% | $150M | -6% |
| Vanguard Portfolio Management LLC | 6.27M | 5.42% | $95M | +0% |
| Vanguard Capital Management LLC | 4.90M | 4.23% | $74.3M | +5% |
| Morgan Stanley | 4.52M | 3.90% | $68.5M | -0% |
| State Street Corp | 2.87M | 2.47% | $43.4M | +12% |
| Geode Capital Management, LLC | 2.80M | 2.42% | $42.4M | +11% |
| Wells Fargo & Company | 2.53M | 2.18% | $38.3M | -14% |
| Quantinno Capital Management LP | 2.22M | 1.92% | $33.7M | -11% |
| Renaissance Technologies LLC | 1.95M | 1.69% | $29.6M | +26% |
| JPMorgan Chase & Co | 1.67M | 1.44% | $25.9M | – |
| Healthcare of Ontario Pension Plan Trust Fund | 1.39M | 1.20% | $21M | +91% |
| Palo Alto Investors LP | 1.28M | 1.11% | $19.4M | No change |
| Nuveen, LLC | 1.23M | 1.06% | $18.7M | +25% |
| Jacobs Levy Equity Management, Inc | 1.16M | 1.01% | $17.6M | -13% |
| Empowered Funds, LLC | 1.15M | 1.00% | $17.5M | – |
| AQR Capital Management LLC | 1.10M | 0.95% | $16.7M | +301% |
| Dimensional Fund Advisors LP | 1.09M | 0.94% | $16.5M | +14% |
| D. E. Shaw & Co., Inc. | 1.02M | 0.88% | $15.5M | +58% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NVCR insiders reported $0 of open-market purchases and $3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Christoph Brackmann | CFO | Sale | 7,343 | $12.86 | $94.4K | Form 4 |
| Nov 9, 2026 | Mukund Paravasthu | Chief Operating Officer | Sale | 3,079 | $12.86 | $39.6K | Form 4 |
| Nov 2, 2026 | Michal Nath Puri | Chief Human Resources Of | Sale | 660 | $13.24 | $8.7K | Form 4 |
| Jun 4, 2026 | Frank X Leonard | CEO | Sale | 34,273 | $17.93 | $615K | Form 4 |
| Jun 2, 2026 | Gabriel Leung | Director | Sale | 2,945 | $15.77 | $46.4K | Form 4 |
| Mar 5, 2026 | Mukund Paravasthu | Chief Operating Officer | Sale | 43,246 | $13.77 | $595K | Form 4 |
| Mar 4, 2026 | Nicolas Leupin | Former Chief Medical Off | Sale | 1,100 | $13.31 | $14.6K | Form 4 |
| Mar 4, 2026 | Uri Weinberg | Chf Medical and Innovati | Sale | 6,412 | $13.31 | $85.3K | Form 4 |
| Mar 4, 2026 | Frank X Leonard | CEO | Sale | 5,607 | $13.31 | $74.6K | Form 4 |
| Mar 4, 2026 | Mukund Paravasthu | Chief Operating Officer | Sale | 5,377 | $13.31 | $71.6K | Form 4 |
| Mar 3, 2026 | William F Doyle | Chair | Sale | 21,330 | $13.43 | $286K | Form 4 |
| Mar 3, 2026 | William F Doyle | Chair | Sale | 50,557 | $12.79 | $647K | Form 4 |
| Mar 2, 2026 | Uri Weinberg | Chf Medical and Innovati | Sale | 3,272 | $13.33 | $43.6K | Form 4 |
| Mar 2, 2026 | Mukund Paravasthu | Chief Operating Officer | Sale | 408 | $13.49 | $5.5K | Form 4 |
| Mar 2, 2026 | Frank X Leonard | CEO | Sale | 7,232 | $13.49 | $97.6K | Form 4 |
| Feb 27, 2026 | Uri Weinberg | Chf Medical and Innovati | Sale | 7,461 | $13.84 | $103K | Form 4 |
| Feb 27, 2026 | Michal Nath Puri | Chief Human Resources Of | Sale | 1,441 | $13.66 | $19.7K | Form 4 |
| Feb 27, 2026 | Mukund Paravasthu | Chief Operating Officer | Sale | 1,555 | $13.66 | $21.2K | Form 4 |
| Feb 27, 2026 | Nicolas Leupin | Former Chief Medical Off | Sale | 1,029 | $13.66 | $14.1K | Form 4 |
| Feb 27, 2026 | Frank X Leonard | CEO | Sale | 9,734 | $13.66 | $133K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| William F Doyle | Executive Chairman, Director | – | $933K | Mar 3, 2026 |
| Frank X Leonard | Chief Executive Officer | – | $920K | Jun 4, 2026 |
| Mukund Paravasthu | Chief Operating Officer | – | $733K | Nov 9, 2026 |
| Uri Weinberg | Chf Medical and Innovation Ofr | – | $232K | Mar 4, 2026 |
| Christoph Brackmann | Chief Financial Officer | – | $94.4K | Nov 9, 2026 |
| Gabriel Leung | Director | – | $46.4K | Jun 2, 2026 |
| Nicolas Leupin | Former Chief Medical Officer | – | $28.7K | Mar 4, 2026 |
| Michal Nath Puri | Chief Human Resources Officer | – | $28.4K | Nov 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NVCR short interest
High short interest. 11.0% of NVCR shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 51%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12.91M NVCR shares were sold short, 11.0% of the shares outstanding, up 0.7% from the report before. At the average daily volume of 2.14M shares, buying them all back would take about 6.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.91M | 11.05% | +1% | 2.14M | 6.0 |
| Oct 15, 2026 | 12.82M | 11.01% | +15% | 1.66M | 7.7 |
| Sep 30, 2026 | 11.16M | 9.59% | -5% | 1.11M | 10.1 |
| Sep 15, 2026 | 11.80M | 10.13% | +9% | 1.03M | 11.5 |
| Aug 31, 2026 | 10.79M | 9.27% | +18% | 1.41M | 7.6 |
| Aug 14, 2026 | 9.17M | 7.87% | -10% | 1.10M | 8.4 |
| Jul 31, 2026 | 10.14M | 8.71% | -12% | 2.07M | 4.9 |
| Jul 15, 2026 | 11.46M | 9.89% | -4% | 1.53M | 7.5 |
| Jun 30, 2026 | 11.88M | 10.26% | +23% | 1.92M | 6.2 |
| Jun 15, 2026 | 9.65M | 8.33% | +5% | 1.62M | 6.0 |
| May 29, 2026 | 9.15M | 7.90% | +7% | 1.32M | 6.9 |
| May 15, 2026 | 8.54M | 7.37% | +23% | 1.99M | 4.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
NovoCure company events
NovoCure filed 19 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementShared information with investors. Filing
- Oct 29, 2026ResultsReleased financial results. Filing
- Oct 1, 2026AnnouncementShared information with investors. Filing
- Sep 9, 2026LeadershipTimothy Scannell, a current director of NovoCure Limited, has retired from the Board and his seat was formally vacated pursuant to the Company’s Articles of Association effective September 2, 2026. Filing
- Sep 1, 2026AnnouncementIn mid-August 2026, NovoCure Limited through a subsidiary, became aware of unauthorized access to some of its information systems. Filing
- Jul 23, 2026ResultsReleased financial results. Filing
- Jun 30, 2026AnnouncementShared information with investors. Filing
- Jun 18, 2026AnnouncementShared information with investors. Filing
- Jun 5, 2026LeadershipNovoCure Limited held its annual general meeting of shareholders. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Apr 24, 2026LeadershipAmended an earlier report. Of the Initial Form 8-K. This Amendment provides a description of the compensation of Frank Leonard in connection with his appointment as Chief Executive Officer effective as of December 1, 2025. Filing
- Apr 9, 2026LeadershipNovoCure Limited, through one of its affiliates, modified the compensation of Uri Weinberg, M.D., Ph.D., a named executive officer of the Company, in connection with his appointment as Chief Medical Officer in addition to his role as Chief Innovation Officer of the Company. Filing
- Mar 26, 2026AnnouncementShared information with investors. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Feb 24, 2026AnnouncementShared information with investors. Filing
- Feb 11, 2026AnnouncementShared information with investors. Filing
- Feb 5, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 1, 2025LeadershipResignation of Chief Executive Officer; Transition of Chief Financial Officer; Resignation of Chief Operating Officer On November 24, 2025, by mutual agreement, Ashley Cordova, Director and Chief Executive Officer of NovoCure Limited resigned as a member of the Board of Directors of NovoCure… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
NovoCure financials
Famous investors that hold NVCR
6 of the 50 well-known investors we track reported holding NVCR in their latest 13F filing. The largest position is Jim Simons's, worth $33.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.12M | $33.8M | 0.0% | +8% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 607,780 | $9.7M | 0.0% | -24% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 445,382 | $7.1M | 0.0% | +183% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 400,060 | $6.4M | 0.0% | +49% |
| Israel Englander · Millennium Management | Q3 2026 | 120,794 | $1.9M | 0.0% | -57% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 29,806 | $475K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NVCR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 9, 2026 | Soleus Capital Master Fund, L.P. | 13G/A | 8.1% |
| Nov 9, 2026 | Soleus Capital Master Fund, L.P. | 13G/A | 8.1% |
Questions about NovoCure Ltd (NVCR) stock
Who owns the most NVCR stock?
The largest reported owner of NovoCure Ltd (NVCR) is FMR LLC (Fidelity), with 15.0% of the company. In total, 214 funds and institutions reported holding NVCR at the end of Q2 2026, together about 90% of the shares. See the largest owners.
Are NVCR insiders buying or selling?
In the last 12 months, NVCR insiders reported no open-market purchases and 20 sales worth $3M. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in NVCR?
As of Oct 30, 2026, 12.91M NVCR shares were sold short, 11.0% of the shares outstanding, up 0.7% from the report before. At the average daily volume of 2.14M shares, buying them all back would take about 6.0 trading days (days to cover). See the history.
Which famous investors hold NVCR?
6 of the 50 well-known investors we track reported NVCR in their latest 13F filing, including Jim Simons, Steve Cohen, Ken Griffin. The largest position is worth $33.8M. See all holders.
Executive pay
NovoCure's chief executive was paid a total of $1.5M for the year ended Dec 31, 2024, up 1% from $1.5M the year before. In the last 12 months, NovoCure's executives and directors bought no stock on the open market and sold $3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.